ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,561 JPY | +2.56% |
|
+3.14% | -7.41% |
Presenter SpeechChikashi Takeda (Executives)Good afternoon, ladies and gentleman. I am Chikash...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,522
JPY
Average target price
1,991
JPY
Spread / Average Target
+30.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.41% | 1.74TCr | |
| +37.74% | 72TCr | |
| +34.31% | 59TCr | |
| -2.07% | 37TCr | |
| +20.25% | 33TCr | |
| +2.99% | 28TCr | |
| +17.06% | 24TCr | |
| +9.73% | 21TCr | |
| -4.17% | 21TCr | |
| +2.81% | 17TCr |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Transcript : Astellas Pharma Inc., Q3 2018 Earnings Call, Jan 31, 2018
